Syndrome of inappropriate antidiuretic hormone classification: Difference between revisions

Jump to navigation Jump to search
Line 31: Line 31:
*Accounts for (20–40%) of the cases
*Accounts for (20–40%) of the cases
*The[[ osmotic]][[ threshold ]]for AVP release is lowered – a [[reset osmostat]] – such that secretion of AVP occurs at lower plasma [[osmolalities]] than normal.   
*The[[ osmotic]][[ threshold ]]for AVP release is lowered – a [[reset osmostat]] – such that secretion of AVP occurs at lower plasma [[osmolalities]] than normal.   
*AVP is suppressed at plasma osmolalities below the lower, reset threshold, further over-hydration leads to suppression of AVP release, which protects against the progression to severe[[ hyponatraemia]].  
*AVP is suppressed at plasma osmolalities below the lower, reset threshold, further over-[[hydration]] leads to suppression of AVP release, which protects against the progression to severe[[ hyponatraemia]].  
*Although most [[tumours]] manifest type A[[ SIADH]], some also present with type B SIADH, so the[[ pattern]] of [[abnormal]][[ AVP]] (arginine vasopressin) secretion cannot be utilized to predict the [[causation]] of SIADH.
*Although most [[tumours]] manifest type A[[ SIADH]], some also present with type B SIADH, so the[[ pattern]] of [[abnormal]][[ AVP]] (arginine vasopressin) secretion cannot be utilized to predict the [[causation]] of [[SIADH]].


|-
|-

Revision as of 16:46, 14 August 2017

Syndrome of inappropriate antidiuretic hormone Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Syndrome of inappropriate antidiuretic hormone classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Syndrome of inappropriate antidiuretic hormone classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Syndrome of inappropriate antidiuretic hormone classification

CDC on Syndrome of inappropriate antidiuretic hormone classification

Syndrome of inappropriate antidiuretic hormone classification in the news

Blogs on Syndrome of inappropriate antidiuretic hormone classification

Directions to Hospitals Treating Syndrome of inappropriate antidiuretic hormone

Risk calculators and risk factors for Syndrome of inappropriate antidiuretic hormone classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

SIADH may be classified into several sub-types based on the pattern of AVP( arginine vasopressin) secretions across a range of plasma osmolalities: Type A, type B, type C, type D.

Classification

SIADH may be classified in to several sub-types based on the pattern ofAVPsecretion across a range of plasmaosmolalities:


Classification Features
TypeA
  • The commonest form of SIADH responsible for a much higher proportion of SIADH, at around 60–70%.
  • Exhibit excessive, random secretion of AVP, with loss of the close linear relationship between plasmaosmolality and plasmaAVP.
  • Common in lung cancer
  • Invitro studies have demonstrated that some lung tumours synthesize AVP, and that tumour tissue stains positive for AVPmRNA
  • Plasma AVP concentrations in type A SIADH are not suppressed physiologically by drinking , which makes patients vulnerable to the development of severe hyponatremia.
  • Studies have also demonstrated a lowerosmotic threshold for thirst appreciation in this type of SIADH.
  • This type of SIADH is also characteristic of nasopharyngeal tumours, which also stain positive for AVPmRNA
Type B
  • Accounts for (20–40%) of the cases
  • Theosmoticthreshold for AVP release is lowered – a reset osmostat – such that secretion of AVP occurs at lower plasma osmolalities than normal.
  • AVP is suppressed at plasma osmolalities below the lower, reset threshold, further over-hydration leads to suppression of AVP release, which protects against the progression to severehyponatraemia.
  • Although most tumours manifest type ASIADH, some also present with type B SIADH, so thepattern of abnormalAVP (arginine vasopressin) secretion cannot be utilized to predict the causation of SIADH.
TypeC
  • A rare condition characterized by failure to suppress AVP secretion at plasma osmolalities below the osmotic threshold.
  • Plasma AVP concentrations are thus inappropriately high at low plasma osmolalities, but there is a normal relationship between plasma osmolality and plasma AVP at physiological plasma osmolalities.
  • This variant may be due to dysfunction of inhibitory neurons in thehypothalamus, leading to persistent low-grade basal AVP secretion.
Type D
  • Type D:
  • Is a rare clinical picture of SIADH with low or undetectableAVP levels and no detectable abnormality in circulating AVP response .
  • It is thought that a nephrogenic SIADH (NSIAD) may be responsible for this picture .
  • Gain-of-functionmutations in the V2 receptor leading to a clinical picture of SIADH, with undetectable AVP levels, have been described.
  • The identified mutations had different nucleotide substitutions causing different levels of V2 receptor activation.
  • This syndrome appears to be inherited in an X-linked manner,although heterozygous females may have varying degrees of inappropriate antidiuresis. Owing to variable expressivity of the gene involved,NSIAD may be clinically undetectable for years, until other contributing factors in later life lead to clinically significant hyponatraemia . [1]

References

  1. Hannon MJ, Thompson CJ (2010). "The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences". Eur. J. Endocrinol. 162 Suppl 1: S5–12. doi:10.1530/EJE-09-1063. PMID 20164214.

Template:WS Template:WH